These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1087 related items for PubMed ID: 12019178
1. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Turner KJ, Moore JW, Jones A, Taylor CF, Cuthbert-Heavens D, Han C, Leek RD, Gatter KC, Maxwell PH, Ratcliffe PJ, Cranston D, Harris AL. Cancer Res; 2002 May 15; 62(10):2957-61. PubMed ID: 12019178 [Abstract] [Full Text] [Related]
3. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Wiesener MS, Münchenhagen PM, Berger I, Morgan NV, Roigas J, Schwiertz A, Jürgensen JS, Gruber G, Maxwell PH, Löning SA, Frei U, Maher ER, Gröne HJ, Eckardt KU. Cancer Res; 2001 Jul 01; 61(13):5215-22. PubMed ID: 11431362 [Abstract] [Full Text] [Related]
4. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. Na X, Wu G, Ryan CK, Schoen SR, di'Santagnese PA, Messing EM. J Urol; 2003 Aug 01; 170(2 Pt 1):588-92. PubMed ID: 12853836 [Abstract] [Full Text] [Related]
8. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma. Clifford SC, Astuti D, Hooper L, Maxwell PH, Ratcliffe PJ, Maher ER. Oncogene; 2001 Aug 16; 20(36):5067-74. PubMed ID: 11526493 [Abstract] [Full Text] [Related]
9. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Wykoff CC, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ. Oncogene; 2000 Dec 14; 19(54):6297-305. PubMed ID: 11175344 [Abstract] [Full Text] [Related]
10. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia. Gunningham SP, Currie MJ, Han C, Turner K, Scott PA, Robinson BA, Harris AL, Fox SB. Cancer Res; 2001 Apr 01; 61(7):3206-11. PubMed ID: 11306510 [Abstract] [Full Text] [Related]
14. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. Smith K, Gunaratnam L, Morley M, Franovic A, Mekhail K, Lee S. Cancer Res; 2005 Jun 15; 65(12):5221-30. PubMed ID: 15958567 [Abstract] [Full Text] [Related]
16. Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Ananth S, Knebelmann B, Grüning W, Dhanabal M, Walz G, Stillman IE, Sukhatme VP. Cancer Res; 1999 May 01; 59(9):2210-6. PubMed ID: 10232610 [Abstract] [Full Text] [Related]
17. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Carroll VA, Ashcroft M. Cancer Res; 2006 Jun 15; 66(12):6264-70. PubMed ID: 16778202 [Abstract] [Full Text] [Related]
18. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene. Liu MY, Poellinger L, Walker CL. Cancer Res; 2003 May 15; 63(10):2675-80. PubMed ID: 12750296 [Abstract] [Full Text] [Related]